Vorolanib for advanced kidney cancer after first treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic kidney cancer with clear cell features that cannot be removed by surgery.
- You are between 18 and 80 years old and able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have not had any other cancer in the last 5 years, except for some easily curable types like certain skin or thyroid cancers.
- You have not had any other anti-cancer treatments (targeted therapy, immunotherapy, or experimental drugs) in the last 4 weeks.
- You do not have brain metastases, active autoimmune disease, or uncontrolled fluid buildup in the chest or belly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment given before surgery for high-risk kidney cancer that hasn't spread far. The goal is to see if it can help shrink the tumor and improve outcomes.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests new drug combinations for kidney cancer that is removable by surgery but may have spread. The goal is to see if these treatments can shrink tumors before surgery and improve outcomes.
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests two new drugs, vorolanib and cadonilimab, for people with advanced kidney cancer that hasn't been treated before. The combination aims to shrink tumors and slow down the cancer's growth.
This trial compares two new treatment options for advanced kidney cancer (clear cell type) that has worsened after immunotherapy. One group gets two oral drugs (vorolanib and everolimus) together; the other gets a standard targeted therapy (sunitinib).
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.